Skip to content
Resources > Reports

Obesity Treatments: An Outsized Opportunity

As the popularity of new obesity treatments continues to rise, debates are raging about the potential impact on business models within healthcare and beyond. Stream Expert Insights in AlphaSense is your single-source solution for superior quality insights on these new developments and market-moving events in life sciences.

In this whitepaper, we explore new GLP-1 based medications that are revolutionizing the obesity care space with premium insights from expert physicians.

Download our whitepaper now to read these first-person perspectives on obesity treatments that are disrupting the healthcare space.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.